Overview

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Status:
Completed

Trial end date:
2018-02-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted

Phase:

Phase 1

Details

Lead Sponsor:

Prilenia
Teva Branded Pharmaceutical Products, R&D Inc.